Home › Funds › SymBiosis Capital Partners, LLC › IVA

SymBiosis Capital Partners, LLC position in IVA

INVENTIVA SA · Health Care

SymBiosis Capital Partners, LLC reported holding 2,354,000 shares of IVA (INVENTIVA SA) in its Q1 2026 13F filing — a position valued at US$13.1M, representing 24.76% of its reported portfolio and ranking #2 among its reported holdings. SymBiosis Capital Partners, LLC has disclosed IVA holdings in 2 of the last 2 reported quarters, going back to Q4 2025.

Latest position (Q1 2026)2.35M sh
Reported value held$13.06M
Portfolio Weight24.76%
First reportedQ4 2025
Last changeReduce
Updated2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

How SymBiosis Capital Partners, LLC's IVA position evolved

SymBiosis Capital Partners, LLC first disclosed a stake in IVA in Q4 2025 at 2,600,000 shares (US$12.1M). The position peaked in Q1 2026 at 2,354,000 shares, worth US$13.1M. Across 2 filings, SymBiosis Capital Partners, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q1 2026) shows 2,354,000 shares valued at US$13.1M — a reduction of -246,000 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q4 2025 2.60M $12.09M New
Q1 2026 2.35M $13.06M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IVA and 13F data

IVA (INVENTIVA SA) is a Health Care company. 94 other funds we track also report a position in IVA — the largest reported positions include Caligan Partners LP (US$30.9M), Samsara BioCapital, LLC (US$23.9M), Paradigm Biocapital Advisors LP (US$15.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IVA

All IVA fund holders →

FAQ

How long has SymBiosis Capital Partners, LLC held IVA?

SymBiosis Capital Partners, LLC has disclosed IVA holdings in 2 of the last 2 reported quarters, going back to Q4 2025.

What is SymBiosis Capital Partners, LLC's current position in IVA?

As of Q1 2026, SymBiosis Capital Partners, LLC holds 2.35M shares of IVA (INVENTIVA SA), valued at $13.06M, representing 24.76% of its reported portfolio and ranking #2.

Has SymBiosis Capital Partners, LLC been buying or selling IVA?

In the latest 13F filing (Q1 2026), SymBiosis Capital Partners, LLC reduced its position in IVA. The position peaked in Q1 2026 at 2.35M shares.

Which other funds hold IVA?

Other major institutional holders of IVA include Caligan Partners LP, Samsara BioCapital, LLC, Paradigm Biocapital Advisors LP, among 94 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.